Biotechnology
Industry
|
Healthcare
Sector
|
Mr. Peter Janssen
CEO
|
XETRA
Exchange
|
DE0005227201
ISIN
|
United States
Country
|
-
Employees
|
-
Last Dividend
|
15 Jul 2015
Last Split
|
-
IPO Date
|
Biotest Aktiengesellschaft is a prominent biopharmaceutical company with a focus on developing, manufacturing, and marketing biological medicines on both a national and international scale. Originally established in 1946 and headquartered in Dreieich, Germany, the company has evolved from Biotest Serum-Institut GmbH to its current form in 1986. Biotest Aktiengesellschaft operates under the umbrella of Grifols, S.A., a global healthcare giant, indicating a strong backing and strategic alignment in the biopharmaceutical domain. With operations segmented into Therapy, Plasma & Services, and Other, Biotest is at the forefront of advancing treatments in hematology, clinical immunology, and intensive care medicine. Its comprehensive portfolio addresses several critical areas, including hemophilia, hepatitis B, immune deficiencies, and other significant conditions requiring acute therapy and prophylaxis.